Synthetic immunity to break down the bottleneck of cancer immunotherapy

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Immunotherapy of Cancer

This article has no abstract.

متن کامل

Prostate cancer immunotherapy: beyond immunity to curability.

Metastatic prostate cancer is the second leading cause of death from cancer in the United States. It is the first prevalent cancer in which overall survival in advanced disease is modestly, but objectively, improved with outpatient delivered dendritic cell-based immunotherapy. More prostate cancer patients have enrolled through Facebook and trusted-site Internet searches in clinical trials for ...

متن کامل

Speciation: Down the bottleneck?

Experiments in which laboratory populations of fruitflies have been repeatedly passed through bottlenecks fail to support 'founder-effect' models of speciation.

متن کامل

Another way to break down

hen yeast secretory proteins are improperly folded, the ER quality control system directs them into the HRD/DER pathway, which targets the proteins for degradation. Blocking the HRD/DER pathway, however, does not completely stop degradation, implying that there must be an alternative way to destroy misfolded secretory proteins. Haynes et al., reporting on page 91, have now characterized that pa...

متن کامل

Innate Immunity-Based Immunotherapy of Cancer

The immune system protects against invading pathogens and transformed cells, including cancer. Mammalian immune system is divided into two major categories, i.e., innate and adaptive immunity. Innate immunity consists of cellular and biochemical defense mechanisms that respond in the early phase after harmful events, such as encounters with microbes or transformed cells. The cellular components...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Science Bulletin

سال: 2015

ISSN: 2095-9273

DOI: 10.1007/s11434-015-0794-z